Update Breast Cancer 2021 Part 1 - Prevention and Early Stages
Standard
Update Breast Cancer 2021 Part 1 - Prevention and Early Stages. / Stickeler, Elmar; Aktas, Bahriye; Behrens, Annika; Belleville, Erik; Ditsch, Nina; Fasching, Peter A; Fehm, Tanja N; Hartkopf, Andreas D; Jackisch, Christian; Janni, Wolfgang; Kolberg-Liedtke, Cornelia; Kolberg, Hans-Christian; Lüftner, Diana; Lux, Michael P; Müller, Volkmar; Schneeweiss, Andreas; Schütz, Florian; Schulmeyer, Carla E; Tesch, Hans; Thomssen, Christoph; Uleer, Christoph; Untch, Michael; Welslau, Manfred; Wöckel, Achim; Wurmthaler, Lena A; Würstlein, Rachel; Thill, Marc.
In: GEBURTSH FRAUENHEILK, Vol. 81, No. 5, 05.2021, p. 526-538.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Update Breast Cancer 2021 Part 1 - Prevention and Early Stages
AU - Stickeler, Elmar
AU - Aktas, Bahriye
AU - Behrens, Annika
AU - Belleville, Erik
AU - Ditsch, Nina
AU - Fasching, Peter A
AU - Fehm, Tanja N
AU - Hartkopf, Andreas D
AU - Jackisch, Christian
AU - Janni, Wolfgang
AU - Kolberg-Liedtke, Cornelia
AU - Kolberg, Hans-Christian
AU - Lüftner, Diana
AU - Lux, Michael P
AU - Müller, Volkmar
AU - Schneeweiss, Andreas
AU - Schütz, Florian
AU - Schulmeyer, Carla E
AU - Tesch, Hans
AU - Thomssen, Christoph
AU - Uleer, Christoph
AU - Untch, Michael
AU - Welslau, Manfred
AU - Wöckel, Achim
AU - Wurmthaler, Lena A
AU - Würstlein, Rachel
AU - Thill, Marc
N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
PY - 2021/5
Y1 - 2021/5
N2 - This review summarises not only the latest evidence on prevention, but also the current research on the treatment of early-stage breast cancer patients. Recent years have seen a growing body of evidence on the risk of high- and moderate-penetrance breast cancer susceptibility genes. A large international consortium has now been able to further refine the answer to the question of the significance of the so-called panel genes. Moreover, the data on treatment selection regarding endocrine efficacy and the decision for or against chemotherapy have also been advanced markedly. There is also new data on adjuvant CDK4/6 (cyclin-dependent kinase 4/6) inhibitors, which are standard in first-line treatment in patients with metastatic HER2-negative, hormone receptor-positive (HR+) breast cancer. For other therapies such as immune checkpoint inhibitors, which have successfully improved the rate of pathologic complete response (pCR) in neoadjuvant treatment settings for patients with triple-negative breast cancer (TNBC), there is a growing understanding of the quality of life and side effects. This is especially important in situations where patients could possibly be cured without such a regimen.
AB - This review summarises not only the latest evidence on prevention, but also the current research on the treatment of early-stage breast cancer patients. Recent years have seen a growing body of evidence on the risk of high- and moderate-penetrance breast cancer susceptibility genes. A large international consortium has now been able to further refine the answer to the question of the significance of the so-called panel genes. Moreover, the data on treatment selection regarding endocrine efficacy and the decision for or against chemotherapy have also been advanced markedly. There is also new data on adjuvant CDK4/6 (cyclin-dependent kinase 4/6) inhibitors, which are standard in first-line treatment in patients with metastatic HER2-negative, hormone receptor-positive (HR+) breast cancer. For other therapies such as immune checkpoint inhibitors, which have successfully improved the rate of pathologic complete response (pCR) in neoadjuvant treatment settings for patients with triple-negative breast cancer (TNBC), there is a growing understanding of the quality of life and side effects. This is especially important in situations where patients could possibly be cured without such a regimen.
U2 - 10.1055/a-1464-0953
DO - 10.1055/a-1464-0953
M3 - SCORING: Journal article
C2 - 34035547
VL - 81
SP - 526
EP - 538
JO - GEBURTSH FRAUENHEILK
JF - GEBURTSH FRAUENHEILK
SN - 0016-5751
IS - 5
ER -